High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.739
+25.21%
--
--
-0.767
+21.73%
--
--
-0.768
+14.69%
Estimates Revision
The market is revising Downward the revenue expectations for Denali Therapeutics Inc. (DNLI) for FY2025, with the revenue forecasts being adjusted by -27.27% over the past three months. During the same period, the stock price has changed by 16.72%.
Revenue Estimates for FY2025
Revise Downward
-27.27%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+6.54%
In Past 3 Month
Stock Price
Go Up
+16.72%
In Past 3 Month
12 Analyst Rating
0Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is 32.44 USD with a low forecast of 27.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
0 Sell
Strong Buy
0Current: 14.870
Low
27.00
Averages
32.44
High
40.00
0Current: 14.870
Low
27.00
Averages
32.44
High
40.00
BofA
Tazeen Ahmad
Buy
downgrade
$28 -> $27
2025-05-19
Reason
BofA
Tazeen Ahmad
Price Target
$28 -> $27
2025-05-19
downgrade
Buy
Reason
BofA analyst Tazeen Ahmad lowered the firm's price target on Denali Therapeutics to $27 from $28 and keeps a Buy rating on the shares. Denali announced they have completed the biologics license application for tividenofusp alfa for Hunter Syndrome and noted the application was submitted under the accelerated approval path, the analyst tells investors. The firm updated its model for Q1 results, cash and share count and increase op expense estimates in line with trend and slightly pushed its near-term estimates for tivi' as it expects a launch in early 2026, the analyst noted.
Baird
Outperform -> NULL
downgrade
$30 -> $29
2025-05-08
Reason
Baird
Price Target
$30 -> $29
2025-05-08
downgrade
Outperform -> NULL
Reason
Baird lowered the firm's price target on Denali Therapeutics to $29 from $30 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the Tivi BLA was submitted and the commercial launch is on track for early 2026.
B. Riley
Mayank Mamtani
Buy
downgrade
$35 -> $30
2025-05-08
Reason
B. Riley
Mayank Mamtani
Price Target
$35 -> $30
2025-05-08
downgrade
Buy
Reason
B. Riley analyst Mayank Mamtani lowered the firm's price target on Denali Therapeutics to $30 from $35 and keeps a Buy rating on the shares following the Q1 report. The firm updated the company's model. FDA-related uncertainty continues to weigh on the stock, but attainment of regulatory and pipeline execution milestones in coming months, alongside visibility into new FDA leadership staff taking form, could bode well for Denali, the analyst tells investors in a research note.
B of A Securities
Tazeen Ahmad
Strong Buy
Maintains
$30 → $28
2025-03-10
Reason
B of A Securities
Tazeen Ahmad
Price Target
$30 → $28
2025-03-10
Maintains
Strong Buy
Reason
Morgan Stanley
Matthew Harrison
Buy
Initiates
$41 → $33
2025-03-07
Reason
Morgan Stanley
Matthew Harrison
Price Target
$41 → $33
2025-03-07
Initiates
Buy
Reason
B. Riley Securities
Mayank Mamtani
Strong Buy
Reiterates
$38 → $35
2025-03-05
Reason
B. Riley Securities
Mayank Mamtani
Price Target
$38 → $35
2025-03-05
Reiterates
Strong Buy
Reason
B. Riley lowered the firm's price target on Denali Therapeutics to $35 from $38 and keeps a Buy rating on the shares following the Q4 report. The company highlighted key corporate priorities aimed at de-risking the path to U.S. FDA approvals for multiple programs within its Enzyme Transport Vehicle franchise, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Denali Therapeutics Inc (DNLI.O) is -4.80, compared to its 5-year average forward P/E of -13.13. For a more detailed relative valuation and DCF analysis to assess Denali Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-13.13
Current PE
-4.80
Overvalued PE
0.21
Undervalued PE
-26.48
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-10.68
Current EV/EBITDA
-2.36
Overvalued EV/EBITDA
-0.95
Undervalued EV/EBITDA
-20.41
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
61.15
Current PS
78.58
Overvalued PS
101.78
Undervalued PS
20.51
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 416.99% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 416.99% over the last month.
Sold
Bought
DNLI News & Events
Events Timeline
(ET)
2025-07-07
10:54:26
Denali noted no FDA panel meeting in call with William Blair
2025-07-07
08:02:22
Denali announces FDA acceptance, priority review for tividenofusp alfa BLA
2025-05-06 (ET)
2025-05-06
16:12:15
Denali Therapeutics reports Q1 EPS (78c), consensus (70c)
Sign Up For More Events
Sign Up For More Events
News
Preview
3.0
07-10NASDAQ.COMLABU's Holdings Imply 58% Gain Potential
Preview
9.0
07-07NASDAQ.COMDenali: FDA To Review BLA Seeking Accelerated Approval For Tividenofusp Alfa
Preview
6.5
06-09NASDAQ.COMAnalysts Anticipate VB To Hit $270
Sign Up For More News
People Also Watch
FAQ
What is Denali Therapeutics Inc (DNLI) stock price today?
What is Denali Therapeutics Inc (DNLI)'s business?
What is the price predicton of DNLI Stock?
What is Denali Therapeutics Inc (DNLI)'s revenue for the last quarter?
What is Denali Therapeutics Inc (DNLI)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Denali Therapeutics Inc (DNLI)'s fundamentals?
How many employees does Denali Therapeutics Inc (DNLI). have?